Results 261 to 270 of about 4,457,527 (301)
Some of the next articles are maybe not open access.
Blood Reviews, 1989
The accepted role for thrombolytic therapy has until recently been limited because of its complexity and side-effects. It has generally been reserved for use systemically in a limited number of patients with acute, major pulmonary embolism or iliofemoral venous thrombosis, and locally in some patients with acute, peripheral arterial occlusion.
openaire +2 more sources
The accepted role for thrombolytic therapy has until recently been limited because of its complexity and side-effects. It has generally been reserved for use systemically in a limited number of patients with acute, major pulmonary embolism or iliofemoral venous thrombosis, and locally in some patients with acute, peripheral arterial occlusion.
openaire +2 more sources
Progress in Intravenous Thrombolytic Therapy for Acute Stroke.
JAMA Neurology, 2015IMPORTANCE Intravenous recombinant tissue plasminogen activator (alteplase) was approved by the US Food and Drug Administration in 1996 for the treatment of acute ischemic stroke.
R. Marshall
semanticscholar +1 more source
Chest, 2004
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines.
J. Ansell +5 more
semanticscholar +1 more source
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines.
J. Ansell +5 more
semanticscholar +1 more source
Thrombolytic therapy in pregnancy
Journal of Thrombosis and Thrombolysis, 2006Pregnancy due to its physiological changes is a procoagulant state. The rate of cardiac valve prosthesis thrombosis, deep venous thrombosis and pulmonary embolism are all increased. Thrombolytic therapy with tissue plasminogen activator (rt-PA) is an approved therapy for ischemic stroke, myocardial infarction, pulmonary embolism and thrombosis of ...
Michael Buerke +4 more
openaire +3 more sources
Chest, 2004
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do,
H. Büller +5 more
semanticscholar +1 more source
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do,
H. Büller +5 more
semanticscholar +1 more source
Monitoring thrombolytic therapy
Progress in Cardiovascular Diseases, 1992HROMBOLYTIC THERAPY for acute myocardial infarction (MI) now represents the standard of care for many patients. A large number of clinical trials have demonstrated improvement in survival and cardiac function following treatment of acute MI with thrombolytic agents,‘.’ and the use of thrombolytic therapy is rapidly spreading to community hospitals.
Russell P. Tracy +5 more
openaire +3 more sources
Thrombolytic therapy for stroke
Current Opinion in Neurology, 1994The physiology of thrombi and the pharmacology of thrombolytic drugs are under active study and improved regimens for the dosing of thrombolytic agents have been developed. In the setting of myocardial infarction, recently reported differences among thrombolytic agents have been slight, including the frequency of thrombolysis-associated hemorrhagic ...
Rashmi Kothari +2 more
openaire +2 more sources
Thrombolytic therapy in the elderly
The Lancet, 2000Elderly patients have the highest absolute risk of death following an acute myocardial infarction (MI); 16.1% for those aged between 65 and 74 years, and 25.3% for those older than 75 years. Therefore, this age-group potentially may benefit most from the use of thrombolytic therapy.
openaire +3 more sources
Applications of thrombolytic therapy
Intensive Care Medicine, 1998Formation of a thrombus involves the aggregation of platelets, precipitation of fibrinogen into a fibrin meshwork and subsequent trapping of red blood cells. The coagulation cascades ensure that this process is initiated in response to a wide range of stimuli including local vessel trauma, endothelial damage and systemic inflammation.
A. Timmis, N. Curzen, R. Haque
openaire +3 more sources
Thrombolytic therapy in children
Thrombosis Research, 2006Thrombolysis is increasingly considered a treatment option in newborns and children with arterial and venous thromboembolic events, or occluded central venous lines. However, no uniform recommendations are available with regard to indications, drug of choice, route of administration, and dosing regimen.
openaire +2 more sources